Nigakinone

Synonyms: 苦木酮碱
Nigakinone 是一种具有口服活性的 FXR 激活剂和 NLRP3 抑制剂,可抑制胆汁酸诱导的炎症与细胞损伤、调控胆汁酸谱并减轻肠黏膜屏障损伤,还能与 Irinotecan (MS-O02109) 协同抑制结直肠癌细胞的增殖、迁移及皮下异种移植瘤的生长,可用于溃疡性结肠炎与结直肠癌的相关研究。
产品编号: MS-Z61158 纯度: 99.95% CAS No.: 18110-86-6 分子式: C15H10N2O3 分子量: 266.25
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价

产品描述

Nigakinone 是一种具有口服活性的 FXR 激活剂和 NLRP3 抑制剂,可抑制胆汁酸诱导的炎症与细胞损伤、调控胆汁酸谱并减轻肠黏膜屏障损伤,还能与 Irinotecan (MS-O02109) 协同抑制结直肠癌细胞的增殖、迁移及皮下异种移植瘤的生长,可用于溃疡性结肠炎与结直肠癌的相关研究。

生物实验数据

生物活性 Nigakinone is an orally active FXR activator and NLRP3 inhibitor that inhibits bile acid-induced inflammation and cell injury, regulates the bile acid profile, and alleviates intestinal mucosal barrier damage; it also synergizes with Irinotecan (MS-O02109) to inhibit the proliferation and migration of colorectal cancer cells and the growth of subcutaneous xenograft tumors, and can be used in research related to ulcerative colitis and colorectal cancer.
IC50 & Target

NLRP3

 

体外研究
(In Vitro)

Nigakinone (10 μM; 24 h) 在 HEK293T 细胞中功能性激活 hFXR,以 hFXR 依赖的方式显著提升 BSEP 启动子活性。
Nigakinone (0.2-5 μM; 24 h) 可通过激活 FXR 缓解 Lithocholic acid (LCA) (MS-A96711) 诱导的 CT26 细胞炎症反应及紧密连接损伤,而该作用在 FXR 沉默细胞中被消除。
Nigakinone (0.2-5 μM) 可显著上调低表达 FXR 的 HCT116 结肠癌细胞中 FXR 蛋白的表达。
Nigakinone (0.2-5 μM) 可显著上调低表达 FXR 的 Caco-2 结直肠癌细胞中 FXR 蛋白的表达。
Nigakinone 在 FXR 低表达的 HCT116 结直肠癌细胞中作为 FXR 激动剂,可诱导 FXR 下游靶基因 FGF19 和 SHP 呈浓度依赖性上调。
Nigakinone 可在高表达 FXR 的 HT-29 结肠癌细胞中作为 FXR 激动剂,显著上调 FXR 下游靶基因 FGF19 和 SHP。
Nigakinone (0.2-5 μM; 48 h) 与 Irinotecan 协同抑制低 FXR 表达的 HCT116、Caco-2 及 HT-29 siFXR 结直肠癌细胞的活力。
Nigakinone (1 μM; 24 h, 48 h) 与 Irinotecan 协同抑制低 FXR 表达的 HCT116、Caco-2 以及 HT-29 siFXR 结直肠癌细胞的迁移。
Nigakinone (1 μM; 48 h) 可与 Irinotecan 协同抑制低 FXR 表达的 HCT116 和 Caco-2 结直肠癌细胞的克隆形成活性。

Cell Viability Assay

Cell Line: FXR-low HCT116, Caco-2, and HT-29 siFXR (FXR-knockdown) colorectal cancer cells
Concentration: 0.2, 1, 5 μM nigakinone; 5, 10, 20 μM irinotecan
Incubation Time: 48 h
Result: Exhibited significant synergistic inhibition of cell viability across all tested cell lines.
Showed Q values predominantly exceeding 1.15 and CI values below 1 across different concentration combinations.
Achieved synergy at lower concentrations than silibinin, a comparable dual FXR inducer/agonist.

Cell Migration Assay

Cell Line: FXR-low HCT116, Caco-2, and HT-29 siFXR colorectal cancer cells
Concentration: 1 μM nigakinone; 10 μM irinotecan
Incubation Time: 24 h, 48 h
Result: Exhibited significant synergistic inhibition of cell migration at both 24 h and 48 h across all tested cell lines.
Showed Q values ranging from 1.15 to 1.61 and CI values ranging from 0.29 to 0.57.
体内研究
(In Vivo)

Nigakinone (25-100 mg/kg;口服;每日;连续 9 天) 可通过激活 FXR 来减轻炎症、保护肠黏膜屏障并调控胆汁酸稳态,从而缓解 DSS (MS-A45736) 诱导的 SD 大鼠溃疡性结肠炎。
Nigakinone (60 mg/kg;口服;每日一次;连续 9 天) 通过抑制 NLRP3 介导的炎症反应、保护肠黏膜屏障,并经激活 FXR 调控胆汁酸肠肝循环,缓解 DSS 诱导的野生型 C57BL/6 小鼠溃疡性结肠炎。
Nigakinone (60 mg/kg;口服;每日一次;连续 9 天) 无法缓解 DSS 诱导的 FXR 敲除型 C57BL/6N 小鼠的溃疡性结肠炎,证实 FXR 是 nigakinone 发挥结肠炎治疗作用的必需条件。
Nigakinone (35 mg/kg;腹腔注射;每日一次;连续 21 天) 可通过上调 FXR 单独抑制结直肠癌异种移植物的生长;当其与 Irinotecan 联用时,可发挥协同抗肿瘤活性,增强对细胞增殖的抑制并诱导细胞凋亡。

Animal Model: Sprague-Dawley (SD) (male, 200-220 g, ulcerative colitis induced by 4% DSS ad libitum for 7 days)
Dosage: 25 mg/kg; 50 mg/kg; 100 mg/kg
Administration: p.o.; daily; 9 days
Result: Significantly reduced body weight loss, lowered DAI scores, decreased myeloperoxidase (MPO) and inducible nitric oxide synthase (iNOS) levels, and alleviated colon tissue damage including mucosal ulceration, crypt loss, and inflammatory infiltration.
Significantly reduced colon tissue mRNA expression of NLRP3 and caspase-1, and protein expression of NLRP3, caspase-1, IL-1β, ASC-2, and pro-caspase-1 (100 mg/kg dose).
Significantly increased colon tissue mRNA expression of tight junction proteins ZO-1, Claudin-1, and Occludin, and protected colonic microvilli and tight junctions (100 mg/kg dose).
Significantly reduced total bile acid (TBA) pool size in serum, liver, ileum, and colon; decreased BA proportion in liver and colon while increasing BA proportion in serum and ileum; shifted BA profile to reduce primary BA and increase secondary BA (100 mg/kg dose).
Significantly increased mRNA and protein expression of FXR in liver and ileum; increased liver mRNA expression of BSEP, ileum mRNA expression of FGF15, ASBT, and IBABP; and decreased liver protein expression of CYP7A1 and NTCP (100 mg/kg dose).
Significantly increased colon tissue mRNA and protein expression of FXR.
Animal Model: C57BL/6 (WT) (male, 20-22 g, ulcerative colitis induced by 3.5% DSS ad libitum for 7 days)
Dosage: 60 mg/kg
Administration: p.o.; daily; 9 days
Result: Significantly reduced body weight loss, lowered DAI scores, reversed colon length shortening, decreased serum levels of MPO, TNF-α, and IL-1β, and reduced colon histological scores and tissue damage.
Significantly increased colon tissue mRNA and protein expression of FXR; reduced mRNA and protein expression of NLRP3, IL-1β, TNF-α, ASC-2, and pro-caspase-1; and increased mRNA and protein expression of tight junction proteins ZO-1 and Claudin-1.
Significantly reduced total BA pool size, decreased BA proportion in liver and colon while increasing BA proportion in serum and ileum, increased liver protein expression of FXR, BSEP, SHP, and OSTβ, decreased liver protein expression of CYP7A1 and NTCP, and increased ileum protein expression of FXR, IBABP, and OSTβ.
Animal Model: C57BL/6N (FXR KO) (male, 20-22 g, ulcerative colitis induced by 3.5% DSS ad libitum for 7 days)
Dosage: 60 mg/kg
Administration: p.o.; daily; 9 days
Result: Did not significantly reduce body weight loss, lower DAI scores, reverse colon length shortening, decrease serum levels of MPO, TNF-α, and IL-1β, or reduce colon histological scores and tissue damage.
Did not significantly reduce colon tissue mRNA or protein expression of NLRP3, IL-1β, TNF-α, ASC-2, or pro-caspase-1, or increase mRNA or protein expression of tight junction proteins ZO-1 and Claudin-1.
Did not significantly reduce total BA pool size, alter BA proportion distribution in serum, liver, ileum, or colon, or regulate liver or ileum protein expression of bile acid transporters and regulators.
Animal Model: BALB/c nude (5-week-old, male, SPF-grade, HCT116 cell-derived subcutaneous xenograft model)
Dosage: 35 mg/kg (single agent); 35 mg/kg (in combination with irinotecan 40 mg/kg)
Administration: i.p.; daily; 21 days (single agent); i.p.; daily (nigakinone) + weekly (irinotecan); 21 days (combination)
Result: Reduced tumor weight relative to the control group.
Significantly upregulated FXR protein expression in tumor tissues compared to the control and irinotecan-only groups.
Decreased Ki67 expression compared to the control group.
Increased cleaved caspase 3 expression compared to the control group.
Produced a synergistic reduction in tumor volume relative to irinotecan alone when combined with irinotecan.
Produced a synergistic reduction in tumor weight relative to irinotecan alone when combined with irinotecan.
Further decreased Ki67 expression compared to irinotecan alone when combined with irinotecan.
Further increased cleaved caspase 3 expression compared to irinotecan alone when combined with irinotecan.
Maintained significant FXR upregulation in tumor tissues when combined with irinotecan.
Showed no significant differences in organ indices (heart, liver, lung, spleen, kidneys, brain) or colon length between nigakinone-treated and control groups, indicating good tolerability.
性状 固体
颜色 Light yellow to yellow

化学信息

分子量 266.25
分子式 C15H10N2O3
CAS No. 18110-86-6
别名 苦木酮碱

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2.14 mg/mL (8.04 mM), Solution.
10% DMSO+90% Saline: < 2.14 mg/mL (8.04 mM), Lower concentrations may be soluble, but exact solubility limit is unknown.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 6.25 mg/mL (23.47 mM; 超声助溶 (<60°C); 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM3.7559 mL18.7793 mL37.5587 mL93.8967 mL
5 mM0.7512 mL3.7559 mL7.5117 mL18.7793 mL
10 mM0.3756 mL1.8779 mL3.7559 mL9.3897 mL
15 mM0.2504 mL1.2520 mL2.5039 mL6.2598 mL
20 mM0.1878 mL0.9390 mL1.8779 mL4.6948 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础